NDAORALTABLETPriority Review
Approved
Nov 2008
Lifecycle
Post-LOE
Competitive Pressure
40/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROMACTA (eltrombopag olamine) is an oral small-molecule thrombopoietin receptor agonist approved in 2008 for treating thrombocytopenia across multiple indications including immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia, and aplastic anemia. It works by binding to and activating the thrombopoietin receptor, stimulating platelet production in bone marrow. The drug addresses a significant clinical gap in patients who require platelet support but cannot tolerate or respond to other therapies.
$558MPart D
Post-LOEDeclining
Post-LOEAs a post-LOE product with $558M in Part D spending, the brand is in managed decline with commercial teams focused on market defense and operational efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State
Started Mar 2023
36 enrolled
Thrombocytopenia
Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State
Started Jan 2020
36 enrolled
Thrombocytopenia
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Started May 2012
10 enrolled
Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)+14 more
Promacta Pregnancy Registry
Started Mar 2010
1 enrolled
Purpura, Thrombocytopaenic, Idiopathic
Worked on PROMACTA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.